Your browser doesn't support javascript.
loading
Short-term symptom improvement in infants with suspected cow's milk protein allergy using amino acid formula: a prospective cohort analysis.
Wilsey, Michael J; Baran, Jessica V; Lamos, Luke; Beacker, Jesse; Florio, Jared; Oliveros, Lea; Sriaroon, Panida; Brown, Jerry M; Vanderhoof, Jon A.
Afiliação
  • Wilsey MJ; Department of Pediatrics, University of South Florida Morsani College of Medicine, Tampa, FL, United States.
  • Baran JV; Pediatric Gastroenterology, Hepatology, and Nutrition of Florida, St. Petersburg, FL, United States.
  • Lamos L; Office of Medical Education, Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, FL, United States.
  • Beacker J; Office of Medical Education, Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, FL, United States.
  • Florio J; Office of Medical Education, Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, FL, United States.
  • Oliveros L; Office of Medical Education, Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, FL, United States.
  • Sriaroon P; Pediatric Gastroenterology, Hepatology, and Nutrition of Florida, St. Petersburg, FL, United States.
  • Brown JM; Department of Pediatrics, Division of Allergy and Immunology, University of South Florida Morsani College of Medicine, Tampa, FL, United States.
  • Vanderhoof JA; Office of Medical Education, Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, FL, United States.
Front Nutr ; 10: 1208334, 2023.
Article em En | MEDLINE | ID: mdl-37408987
ABSTRACT

Background:

Cow's milk protein allergy (CMPA) occurs commonly in infants. While the long-term efficacy of amino acid formulas for managing CMPA is well-established, there is limited data on the short-term symptom improvement of using amino acid formula (AAF).

Objective:

This study aimed to determine the short-term effects of managing suspected CMPA in infants aged 6 months and under using a commercial AAF.

Methods:

Healthcare providers who treated infants with suspected CMPA aged 6 months or younger (n = 104) provided de-identified survey data in this prospective study. Healthcare providers scored symptoms for severity from 0 to 3 (none, low, moderate, severe) before using a commercial AAF at Visit 1 and at Visit 2 (3-6 weeks later).

Results:

Gastrointestinal (94%), skin (87%), respiratory (86%), and uncategorized symptoms (89%) improved from AAF initiation, and these findings were consistent across different follow-up visit durations.

Conclusion:

This study is the most extensive prospective analysis conducted in the United States examining the short-term change in suspected CMPA symptoms using an AAF. These findings suggest that AAF may decrease the severity of suspected CMPA symptoms in infants 6 months or younger, often by the next follow-up visit. Further randomized controlled trials are required to confirm these initial findings.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article